

---

primary studies - published RCT

## **Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas.**

**Code:** PM8420740

**Year:** 1993 **Date:** 1993

**Author:** Heijerman HG

### **Study design (if review, criteria of inclusion for studies)**

double-blind placebo-controlled crossover study

### **Participants**

11 adult cystic fibrosis (CF) patients with a fecal fat excretion of more than 10% during treatment with pancrease 2 capsules three times a day.

### **Interventions**

20 mg omeprazole

### **Outcome measures**

fecal fat excretion

### **Main results**

Adjunct therapy with omeprazole resulted in a reduction of fecal fat excretion in patients with residual pancreatic function. This improvement showed significant positive correlations with urinary PABA excretion and the increase in serum PP after the meal (P

### **Authors' conclusions**

the addition of omeprazole to pancrease is most successful in CF patients with residual pancreatic function, determined by urinary PABA excretion or incremental PP.

<http://dx.doi.org/10.1007/BF01296765>

### **See also**

Digestive diseases and sciences YR: 1993 VL: 38 NO: 1

### **Keywords**

Adult; Gastrointestinal Agents; Omeprazole; Pancreatic Enzyme Replacement Therapy; pharmacological\_intervention; Pancreas insufficiency; Pancreatic Diseases; Gastrointestinal Diseases; Malabsorption; Nutrition Disorders; Proton pump inhibitors;